Sugi Predict

Sugi Predict / Compounds / SCHEMBL1966533

SCHEMBL1966533

SCHEMBL1966533

O=C1CCN(C(=O)OCc2ccccc2)CC1F

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ NPC1 O15118 3/20 0.54
▸ RAB9A P51151 3/20 0.54
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ TMEM97 Q5BJF2 3/20 0.45
▸ SIGMAR1 Q99720 3/20 0.45
▸ GRIN2B Q13224 3/20 0.45
▸ HTT P42858 1/20 0.45
▸ PTGDR2 Q9Y5Y4 2/20 0.44
▸ PDK1 Q15118 1/20 0.44
▸ PDK2 Q15119 1/20 0.44
▸ PDK3 Q15120 1/20 0.44
▸ PDK4 Q16654 1/20 0.44
▸ GRM5 P41594 1/20 0.44
▸ HTR2C P28335 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29787241 1.00 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL16903357 0.92 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL18084844 0.91 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL26098605 0.89 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL16903379 0.88 SMN1; SMN2 (0.64) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL4484409 0.87 GRIN2B (0.47) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL731849 0.86 F13A1 (0.43) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL16382728 0.84 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL29710177 0.84 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL322321 0.84 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 — — EP disclosed
WO-2025137507-A1 SOS1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. (US) 2025-06-26 — — WO disclosed
EP-4568951-A1 HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2025-06-18 — — EP disclosed
CN-120136863-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-06-13 — — CN disclosed
CN-120025327-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-05-23 — — CN disclosed
CN-120025328-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-05-23 — — CN disclosed
EP-3340988-B1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI INC (US) 2025-04-09 — — EP disclosed
US-12264134-B2 Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME LLC (US) 2025-04-01 — — US disclosed
CN-119654314-A Heterocyclic amide and urea compounds as JAK2 inhibitors 艾捷斯治疗公司 2025-03-18 — — CN disclosed
CN-114929694-B Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-02-07 — — CN disclosed
WO-2006113471-A2 N-ALKYL-AZACYCLOALKYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2006-10-26 — — WO disclosed
WO-2006113471-A2 N-ALKYL-AZACYCLOALKYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2006-10-26 — — WO disclosed
US-20060234984-A1 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator MERCK & CO., INC. 2006-10-19 — — US disclosed
WO-2006101780-A1 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2006-09-28 — — WO disclosed
EP-1664026-A1 MITOTIC KINESIN INHIBITORS Merck & Co., Inc. (US) 2006-06-07 — — EP disclosed
WO-2005102996-A2 A PROCESS FOR THE PREPARATION OF 2,2-DISUBSTITUTED PYRROLES MERCK & CO., INC. (US) 2005-11-03 — — WO disclosed
WO-2005019206-A1 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2005-03-03 — — WO disclosed
WO-2005019205-A1 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2005-03-03 — — WO disclosed
US-20050043357-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2005-02-24 — — US disclosed
US-20050038074-A1 Mitotic kinesin inhibitors COLEMAN PAUL J (US) 2005-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060234984-A1 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator KIF5B, KIF2C, KIF5C SMN1; SMN2 1979/4885NPC1 1011/4885RAB9A 1615/4885
US-20050043357-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIF18B SMN1; SMN2 1987/4885NPC1 1291/4885RAB9A 1418/4885
US-20050038074-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIF18B SMN1; SMN2 1987/4885NPC1 1291/4885RAB9A 1418/4885
US-12264134-B2 Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, AADAC SMN1; SMN2 2974/4885NPC1 2094/4885RAB9A 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.